Cargando…

Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis

BACKGROUND: Serelaxin, recombinant human relaxin-2, is a hormone with vasodilatory and end-organ protective effects. Recently, it has been licensed to treat acute decompensated heart failure. Here, a systematic review and meta-analysis on randomized controlled trials (RCTs) was performed to assess t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Ling, Cao, Lijuan, Sun, Jing, Li, Zhongyi, Yao, Fengzhen, Zhou, Yabin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023957/ https://www.ncbi.nlm.nih.gov/pubmed/29923986 http://dx.doi.org/10.1097/MD.0000000000011010

Ejemplares similares

Protection from cigarette smoke‐induced vascular injury by recombinant human relaxin‐2 (serelaxin)
por: Pini, Alessandro, et al.
Publicado: (2016)

Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation
por: Leo, Chen Huei, et al.
Publicado: (2014)

Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model
por: Schiffner, René, et al.
Publicado: (2018)

Porcine Relaxin but Not Serelaxin Shows Residual Bioactivity after In Vitro Simulated Intestinal Digestion—Clues for the Development of New Relaxin Peptide Agonists Suitable for Oral Delivery
por: Pacini, Lorenzo, et al.
Publicado: (2022)

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023)

Altered Cerebral Blood Flow and Potential Neuroprotective Effect of Human Relaxin-2 (Serelaxin) During Hypoxia or Severe Hypovolemia in a Sheep Model
por: Schiffner, René, et al.
Publicado: (2020)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Chronic Exposure to Cigarette Smoke Affects the Ileum and Colon of Guinea Pigs Differently. Relaxin (RLX-2, Serelaxin) Prevents Most Local Damage
por: Traini, Chiara, et al.
Publicado: (2022)

Human Relaxin-2 (Serelaxin) Attenuates Oxidative Stress in Cardiac Muscle Cells Exposed In Vitro to Hypoxia–Reoxygenation. Evidence for the Involvement of Reduced Glutathione Up-Regulation
por: Nistri, Silvia, et al.
Publicado: (2020)

Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection
por: Díez, Javier, et al.
Publicado: (2016)

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF
por: Liu, Licette C. Y., et al.
Publicado: (2016)

Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy
por: Nonhoff, Justus, et al.
Publicado: (2017)

Relaxin, a pleiotropic vasodilator for the treatment of heart failure
por: Teichman, Sam L., et al.
Publicado: (2008)

Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions
por: Díez, Javier
Publicado: (2014)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Serelaxin Improves Regional Myocardial Function in Experimental Heart Failure: An In Vivo Cardiac Magnetic Resonance Study
por: Lapinskas, Tomas, et al.
Publicado: (2020)

Relaxin: Review of Biology and Potential Role in Treating Heart Failure
por: Teichman, Sam L., et al.
Publicado: (2010)

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Differences in the renal antifibrotic signaling of serelaxin and zaprinast
por: Wetzl, Veronika, et al.
Publicado: (2015)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure
por: Ponikowski, Piotr, et al.
Publicado: (2014)

Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
por: McCarthy, Joseph C., et al.
Publicado: (2017)

Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling
por: Devarakonda, Teja, et al.
Publicado: (2022)

Serelaxin Alleviates Fibrosis in Thyroid-Associated Ophthalmopathy via the Notch Pathway
por: Sun, Anqi, et al.
Publicado: (2023)

Relaxin'
Publicado: (1983)

Relaxin
por: DeCherney, Alan H.
Publicado: (1982)

Relaxin Level in Patients With Atrial Fibrillation and Association with Heart Failure Occurrence: A STROBE Compliant Article
por: Zhou, Hao, et al.
Publicado: (2016)

Relaxin reverses inflammatory and immune signals in aged hearts
por: Martin, Brian, et al.
Publicado: (2018)

Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-Mediated Airway Relaxation
por: Lam, Maggie, et al.
Publicado: (2016)

Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
por: Bennett, Robert G, et al.
Publicado: (2017)

Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats
por: Wang, Dong, et al.
Publicado: (2017)

Characterizing relaxin receptor expression and exploring relaxin’s effect on tissue remodeling/fibrosis in the human bladder
por: Diaz, Edward C., et al.
Publicado: (2020)

Relaxin Family Member Insulin‐Like Peptide 6 Ameliorates Cardiac Fibrosis and Prevents Cardiac Remodeling in Murine Heart Failure Models
por: Maruyama, Sonomi, et al.
Publicado: (2018)

Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling
por: Formigli, Lucia, et al.
Publicado: (2007)

Relaxin reverses maladaptive remodeling of the aged heart through Wnt-signaling
por: Martin, Brian, et al.
Publicado: (2019)

The effect of relaxin on the musculoskeletal system
por: Dehghan, F, et al.
Publicado: (2014)

The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!
por: Dschietzig, Thomas Bernd, et al.
Publicado: (2020)

Role of relaxin-2 in human primary osteosarcoma
por: Ma, Jinfeng, et al.
Publicado: (2013)

Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance
por: Leo, Chen Huei, et al.
Publicado: (2017)

Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin
por: Wetzl, Veronika, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n51qjhhsblpekure5bfsdt7obo